Trial Profile
A retrospective study to demonstrate the amrubicin efficacy as a third or later line of chemotherapy in patients treated with non-small-cell lung cancer (NSCLC).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Dec 2015
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Dec 2015 New trial record